Intravesical Botulinum Toxin A Injections in patients on antiplatelet and anticoagulation therapy
BAUS ePoster online library. Mensah E. Jun 25, 2019; 259571; P7-7 Disclosure(s): Nil
Ms. Elsie Ellimah Mensah
Ms. Elsie Ellimah Mensah
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
INTRODUCTION

There is little evidence regarding the safety of Intravesical botulinum Toxin-A(Botox) injections in patients on anticoagulant/antiplatelet(AC/AP) medication. The cessation of which may predispose to thromboembolic or ischaemic events. We reviewed significant bleeding events after Botox injection with concurrent AC/AP use.
Methods
A retrospective review of all patients having Botox in 3 London hospitals was conducted between January 2016-July 2018 to examine those with continued AC/AP therapy. Demographic data, indication for injection, and significant bleeding requiring intervention were recorded.
Results
532 patients had Botox injections during this time. 63 patients [mean age 69 years (range 19-89), had a total of 114 separate rounds of Botox injections whilst on treatment dose AC/AP therapy. Each patient had between 1-7 repeat Botox injections. AC/AP use included; aspirin 44, clopidogrel 37, warfarin 19, NOAC (novel/non-vitamin K oral anticoagulant) 14. Patients on warfarin all had INR < 3.
There was 1/114(0.88%) episode of post-injection haematuria requiring overnight admission resolving spontaneously. This patient, on rivaroxiban had 300U of Botox injected through 20 sites, on a background of previous prostate radiotherapy. There was no report of bladder washout or transfusion.
Conclusions
Very few significant bleeding events occurred despite continuation of AC/AP therapy. Some patients within this group may have other factors that further increase bleeding risk. This is an important consideration during patient counselling, and when treating patients who have high risk of thrombosis with AC/AP.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings